Emmaus Seeks Approval of Endari in United Arab Emirates

Emmaus Seeks Approval of Endari in United Arab Emirates

310547

Emmaus Seeks Approval of Endari in United Arab Emirates

Emmaus Life Sciences is seeking the approval of Endari (L-glutamine), an oral treatment for sickle cell disease (SCD), in the the United Arab Emirates (UAE). “We look forward to working with the U.A.E Ministry of Health to bring this important medication to our patient population in the Emirates,” George Sekulich, senior vice president of global commercialization at Emmaus, said in a press release. Review of the company’s application is expected to take 10 to 12…

You must be logged in to read/download the full post.